Type 2 Diabetes Mellitus Clinical Trial
— Soli-CGMOfficial title:
A 16-week, Multicenter, Prospective, Open-label, Single-arm, Phase 4 Study to Evaluate the Effect of Soliqua™ 100/33 on the Percentage of Time in Range (TIR) From Continuous Glucose Monitoring (CGM) in Insulin-naïve Patients With Very Uncontrolled Type 2 Diabetes Mellitus
Verified date | April 2023 |
Source | Sanofi |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of the study is to demonstrate if Soliqua 100/33 improves glycemic control (as measured by Time in Range) and glycemic variability in participants with very uncontrolled (HbA1c ≥ 9%) type 2 Diabetes Mellitus (T2DM) while on at least 2 oral antidiabetic drugs [OADs] with or without a glucagonlike peptide 1 receptor agonist [GLP1 RA]), as measured by continuous glucose monitoring (CGM). The total study duration per participant will be approximately 22 weeks. Three site visits, 3 site or home visits, and up to 13 phone contacts are scheduled. - A screening period of up to 2 weeks - A run-in period of up to 2 weeks and includes the baseline period - A 16-week, open-label treatment period - A 2-week post-treatment safety follow-up period
Status | Completed |
Enrollment | 72 |
Est. completion date | April 14, 2023 |
Est. primary completion date | March 28, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Diagnosed with Type 2 Diabetes mellitus (T2DM) for at least 6 months before the baseline period - HbA1c =9-13% during the run-in period - On at least 2 OADs with or without GLP-1 RA with stable doses (for both) for 3 months prior to the screening period - Willing and able to wear the CGM device continuously for 14 days to capture CGM measures at baseline until the next site visit and again towards the end of the treatment period - Willing and able to prick fingers a minimum of 2-4 times per week utilizing sterile lancets provided along with a manual blood glucose meter kit - Willing to discontinue the daily (oral or injectable) or weekly GLP-1 RA or DPP 4i prior to administration of Soliqua 100/33 - Willing and able to inject Soliqua 100/33 and increase dose as needed to achieve SMPG target - Non-pregnant, non-breastfeeding women utilizing a high-effective contraceptive method or of non-childbearing potential Exclusion Criteria: - Type1 Diabetes mellitus (T1DM) or any other types of diabetes, except T2DM - On meglitinides (eg, nateglinide, repaglinide) - Body mass index (BMI) >40 kg/m² during the screening period - Any current or previous skin conditions, including (but not limited to) severe psoriasis, burns, eczema, scarring, excessive tattoos, that would inhibit the proper wearing of the CGM device - History of severe nausea and vomiting leading to subsequent discontinuation of GLP-1 RA - Known history or presence of clinically significant pancreatitis or gastroparesis - Participants with an episode of severe hypoglycemia or with hypoglycemia unawareness (defined as the onset of neuroglycopenia before the appearance of autonomic warning symptoms [for example, blurred vision, difficulty speaking, feeling faint, difficulty thinking, and confusion] or as the failure to sense a significant fall in blood glucose below normal levels) diagnosed within the 6 months prior to the screening period - Participants with personal or immediate family history of medullary thyroid cancer (MTC) or genetic conditions that predisposes to MTC (eg, multiple endocrine neoplasia syndromes) - Significant current (within past 2 months) and/or expected use of medications known to affect glycemia (eg, =5 mg/day prednisone) - Use of substances known to interfere with CGM readings, such as aspirin-containing products (>650 mg/day of salicylic acid) or supplements containing vitamin C (>1000 mg/day of ascorbic acid) during the 14 days of CGM at either baseline or end of treatment period - Previous treatment with any insulin (except for short term treatment due to intercurrent illness, including gestational diabetes, at the discretion of the investigator) - Has used weight loss drugs (including over the counter and herbal medications) within 12 weeks before the screening visit The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial |
Country | Name | City | State |
---|---|---|---|
United States | Hassman Research Institute - HRI - Berlin - CenExel - PPDS-Site Number:8400007 | Berlin | New Jersey |
United States | Clearview Medical Research LLC-Site Number:8400003 | Canyon Country | California |
United States | Endocrinology Associates Inc-Site Number:8400011 | Columbus | Ohio |
United States | University of Texas Southwestern Medical Center-Site Number:8400018 | Dallas | Texas |
United States | National Research Institute - ClinEdge - PPDS-Site Number:8400004 | Huntington Park | California |
United States | National Research Institute - ClinEdge - PPDS-Site Number:8400009 | Huntington Park | California |
United States | Palm Research Center, Inc.-Site Number:8400005 | Las Vegas | Nevada |
United States | Torrance Clinical Research Institute-Site Number:8400008 | Lomita | California |
United States | Downtown LA Research Center Inc - ClinEdge - PPDS-Site Number:8400001 | Los Angeles | California |
United States | University of Tennessee Health Science Center-Site Number:8400017 | Memphis | Tennessee |
United States | Floridian Research Institute-Site Number:8400013 | Miami | Florida |
United States | Premier Research Associate-Miami-Site Number:8400002 | Miami | Florida |
United States | Mid Hudson Medical Research PLLC-Site Number:8400014 | New Windsor | New York |
United States | Flourish Research - San Antonio - PPDS-Site Number:8400006 | San Antonio | Texas |
United States | Northeast Clinical Research of San Antonio LLC-Site Number:8400019 | Schertz | Texas |
United States | Consano Clinical Research LLC-Site Number:8400010 | Shavano Park | Texas |
United States | University Clinical Investigators Inc-Site Number:8400020 | Tustin | California |
United States | San Fernando Valley Health Institute - ClinEdge - PPDS-Site Number:8400012 | West Hills | California |
Lead Sponsor | Collaborator |
---|---|
Sanofi |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline to week 16 in the percentage of Time in Range (TIR) | TIR defined as 70-180 mg/dL | Baseline, Week 16 | |
Secondary | Change from baseline to Week 16 in coefficient of variation (CV) | Baseline, Week 16 | ||
Secondary | Change from baseline to Week 16 in mean daily blood glucose | Baseline, Week 16 | ||
Secondary | Change from baseline to Week 16 in the maximum Post Prandial Glucose exposure in the 4 hours post-breakfast meal | Baseline, Week 16 | ||
Secondary | Change from baseline to Week 16 in Time above range (TAR) | TAR defined as > 180mg/dL | Baseline, Week 16 | |
Secondary | Percentage of participants achieving CV <36% | Week 16 | ||
Secondary | Change from baseline to Week 16 in TIR per time blocks | TIR (70-180 mg/dL) for specific time blocks defined as 6 am-12 pm; 12 pm-6 pm; 6 pm-12 am, and 12 am-6 am | Baseline, Week 16 | |
Secondary | Percentage of participants achieving Glucose Management Indicator (GMI) | GMI < 7% and < 9% | Week 16 | |
Secondary | Change from baseline to Week 16 in the 4-hour PPG area under the concentration time curve (AUC0-4h) | After start of the breakfast meal | Baseline, Week 16 | |
Secondary | Change from baseline to Week 16 in Time to reach maximum PPG concentration (Tmax) | After start of the breakfast meal | Baseline, Week 16 | |
Secondary | Percentage of participants who spend <15 minutes/day at a glucose level <54 mg/dL | Week 16 | ||
Secondary | Change from baseline to Week 16 in diabetes medication treatment satisfaction scores | The Diabetes Medication Satisfaction Tool (DM SAT) questionnaire is a 16-item measure with higher score indicative of better satisfaction | Baseline, Week 16 | |
Secondary | Number of participants with confirmed hypoglycemia | Including overall hypoglycemia, hypoglycemia with glucose concentration <70 mg/dL (3.9 mmol/L) but =54 mg/dL (3.0 mmol/L), <54 mg/dL (3.0 mmol/L) and severe hypoglycemia | Baseline up to end of study (Week 18) | |
Secondary | Number of participants with adverse events | Baseline up to end of study (Week 18) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02771093 -
An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus
|
Phase 4 | |
Completed |
NCT02545842 -
Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)
|
Phase 4 | |
Recruiting |
NCT03436212 -
Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump.
|
N/A | |
Completed |
NCT03244800 -
A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
|
Phase 2 | |
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Withdrawn |
NCT02769091 -
A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06065540 -
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
|
Phase 3 | |
Recruiting |
NCT05008276 -
Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
|
||
Completed |
NCT04091373 -
A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide
|
Phase 1 | |
Completed |
NCT03296800 -
Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT05979519 -
Fresh Carts for Mom's to Improve Food Security and Glucose Management
|
N/A | |
Recruiting |
NCT06212778 -
Relationship Between Nutritional Status, Hand Grip Strength, and Fatigue in Hospitalized Older Adults With Type 2 Diabetes Mellitus.
|
||
Recruiting |
NCT05579314 -
XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT03859934 -
Metabolic Effects of Melatonin Treatment
|
Phase 1 | |
Terminated |
NCT03684642 -
Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
|
Phase 3 | |
Completed |
NCT03248401 -
Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT03644134 -
A Personalized Intervention to Manage Physiological Stress and Improve Sleep Patterns
|
N/A | |
Completed |
NCT05295160 -
Fasting-Associated Immune-metabolic Remission of Diabetes
|
N/A | |
Completed |
NCT02836873 -
Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment
|
Phase 3 | |
Completed |
NCT02226003 -
Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)
|
Phase 3 |